What's the typical yervoy dose for melanoma?

How much Yervoy is given for melanoma?

Yervoy (ipilimumab) is dosed at 3 mg per kilogram of body weight, given as an intravenous infusion over 90 minutes. This base dose applies to both adjuvant treatment and metastatic melanoma, with schedules differing according to treatment stage.

When does the dose change for metastatic melanoma?

For metastatic melanoma, patients receive 3 mg/kg every three weeks for four doses. The treatment stops after these four doses regardless of progress, because clinical trials showed limited benefit from continuing beyond this point.

What happens if a patient needs maintenance doses?

Maintenance doses are not part of the standard regimen anymore. Early protocols gave 10 mg/kg every 12 weeks indefinitely, but later studies and regulatory updates showed no survival benefit over the 3 mg/kg four-dose schedule, so that approach was discontinued.

What is the dose for adjuvant therapy after surgery?

In adjuvant use, patients receive 10 mg/kg every three weeks for four doses, then 10 mg/kg every 12 weeks for up to three years or until disease recurrence or unacceptable toxicity.

How does Yervoy combine with Opdivo?

In the CheckMate-067 study, Yervoy was combined with Opdivo at 3 mg/kg along with 1 mg/kg Opdivo every three weeks for four doses, then Opdivo alone at 240 mg flat dose. This combination approach is now common for previously untreated advanced melanoma.

Why are companies challenging this patent?

Yervoy's composition-of-matter patent expired in 2013. Remaining patents cover manufacturing methods and formulation methods, which are being challenged through inter partes review. Companies looking for biosimilar opportunities are attacking these secondary patents.

When does the exclusivity expire?

The last exclusivity period for Yervoy ends October 2025. The drug itself is still under some form of active protection through 2025, but biosimilars may reach the market after that point.

Who makes Yervoy?

Yervoy is made by Bristol-Myers Squibb.